International Stem Cell Corporation (OTCBB:ISCO),
www.internationalstemcell.com,
announced today that its new cell production facility has passed final
building inspection, which will enable development and manufacturing of
the company and its partners’ clinical-grade stem cell products.
ISCO has designed and built a unique cell manufacturing facility in
Oceanside, California consisting of separate “suites” for development
and production of different cell types from the company’s proprietary
human parthenogenic stem cell (hpSC) technology. The facility is located
in close proximity to the fertility clinics that provide donated human
eggs (oocytes) under ISCO’s recently-established partnerships and also
near leading Californian research institutions with whom ISCO
collaborates on fundamental stem cell biology and therapeutic
applications.
ISCO will implement its parthenogenic stem cell processes at this
facility during 2010 and adopt current good manufacturing practice
(cGMP) standards. In parallel, ISCO will collaborate with world-leading
scientists to demonstrate the therapeutic applicability and the
potential immune-rejection advantages of hpSC lines relative to other
stem cell classes.